ES2066896T3 - Forma oral de farmaco de lipidos. - Google Patents

Forma oral de farmaco de lipidos.

Info

Publication number
ES2066896T3
ES2066896T3 ES90106947T ES90106947T ES2066896T3 ES 2066896 T3 ES2066896 T3 ES 2066896T3 ES 90106947 T ES90106947 T ES 90106947T ES 90106947 T ES90106947 T ES 90106947T ES 2066896 T3 ES2066896 T3 ES 2066896T3
Authority
ES
Spain
Prior art keywords
solid component
lipid
lipids
semi
oral form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90106947T
Other languages
English (en)
Inventor
Rainer K Dr Liedtke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmed GmbH
Original Assignee
Pharmed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmed GmbH filed Critical Pharmed GmbH
Application granted granted Critical
Publication of ES2066896T3 publication Critical patent/ES2066896T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PARA MEJORAR LA RESORCION DE SUSTANCIAS ACTIVAS, QUE DESPUES DE LA APLICACION ORAL NO ADOPTEN UNA FORMA FACILMENTE ASIMILABLE, SE PREPARA EL MEDICAMENTO ORAL CON LIPIDOS POR MEDIO DE LA COMBINACION DE COMPONENTES LIPOFILOS SEMISOLIDOS CON UN COMPONENTE SOLIDO SOLUBLE EN AGUA. EL COMPONENTE SEMISOLIDO ES UNA MEZCLA HOMOGENEA DE LIPIDOS EN FORMA DE GRASA DURA CON PROPIEDADES DE FUSION REVERSIBLES, QUE A LA TEMPERATURA DEL CUERPO ES LIQUIDA EN UN 95 %. EL COMPONENTE SOLIDO ES UNA ENVOLVENTE SOLUBLE EN AGUA DE GELATINA O ALMIDON.
ES90106947T 1989-06-19 1990-04-11 Forma oral de farmaco de lipidos. Expired - Lifetime ES2066896T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3919982A DE3919982A1 (de) 1989-06-19 1989-06-19 Orale lipidarzneiform

Publications (1)

Publication Number Publication Date
ES2066896T3 true ES2066896T3 (es) 1995-03-16

Family

ID=6383046

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90106947T Expired - Lifetime ES2066896T3 (es) 1989-06-19 1990-04-11 Forma oral de farmaco de lipidos.

Country Status (6)

Country Link
US (1) US5120710A (es)
EP (1) EP0403748B1 (es)
JP (1) JPH0334922A (es)
AT (1) ATE117547T1 (es)
DE (2) DE3919982A1 (es)
ES (1) ES2066896T3 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5109118A (en) * 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
EP0533938A4 (en) * 1991-02-19 1993-06-16 Tsumura & Co. Composition for rectal administration of difficultly absorbable peptide
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
DE4208552A1 (de) * 1992-03-17 1993-09-23 Liedtke Pharmed Gmbh Topische arzneiformen mit insulin
SE9300937L (sv) * 1993-03-19 1994-09-20 Anne Fjellestad Paulsen Komposition för oral administrering av peptider
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
FR2712823B1 (fr) * 1993-11-25 1996-02-23 Scherer Sa Rp Capsule molle de gélatine renfermant un mélange à forte teneur en eau.
JPH08208510A (ja) * 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
RU2172183C2 (ru) * 1995-08-25 2001-08-20 Сангстат Медикал Корпорейшн Оральные циклоспориновые составы
DE19546159A1 (de) 1995-12-11 1997-06-12 Liedtke Pharmed Gmbh Methode und Zusammensetzung einer topisch wirksamen Therapie postoperativer und posttraumatischer Wundschmerzen
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5726154A (en) * 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6455066B1 (en) 2000-03-10 2002-09-24 Epicept Corporation Intradermal-penetration agents for topical local anesthetic administration
US7670626B2 (en) * 2001-07-02 2010-03-02 Merrion Research Iii Limited Delivery of a bioactive material
DE102006001554A1 (de) * 2006-01-05 2007-07-12 Ipc Process-Center Gmbh & Co. Micropellets für die Herstellung von Tiernahrungspellets
CN101772352B (zh) * 2007-09-27 2012-05-23 理研维他命株式会社 软胶囊填充用液态组合物
JP5156458B2 (ja) * 2008-03-31 2013-03-06 理研ビタミン株式会社 ソフトカプセル充填用液状組成物
US20100080773A1 (en) * 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
TR201909840T4 (tr) 2011-03-11 2019-07-22 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antikorları ve kullanımları.
US11065206B2 (en) 2011-06-29 2021-07-20 Avidas Pharmaceuticals, LLC Topical formulations including lipid microcapsule delivery vehicles and their uses
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
JP7306718B2 (ja) 2017-03-13 2023-07-11 エスディージー インコーポレイテッド 向上した安定性を有する脂質ベースのナノ粒子
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5257313A (en) * 1975-11-07 1977-05-11 Yamanouchi Pharmaceut Co Ltd Manufacture of micellar insuline emulsion preparations
US4202888A (en) * 1976-07-12 1980-05-13 Kali-Chemie Pharma Gmbh. Readily enterally absorbable pharmaceutical compositions of cardiac glycosides and preparation thereof
DE2631214A1 (de) * 1976-07-12 1978-01-26 Kali Chemie Pharma Gmbh Verfahren zur erhoehung der loeslichkeit von schwerloeslichen arzneistoffen zum zwecke deren applikation in gelatinekapseln
BE861612A (fr) * 1977-12-07 1978-06-07 Kali Chemie Pharma Gmbh Preparations fortement resorbables par voie enterale de medicaments peu resorbables de nature et procede pour la preparation de celles-ci
JPS5517328A (en) * 1978-07-21 1980-02-06 Tanabe Seiyaku Co Ltd Insulin-containing emulsion and its preparation
DE3171774D1 (en) * 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
GB2118040A (en) * 1982-02-15 1983-10-26 Hoechst Uk Ltd Oral anti-diabetic preparation
DE3374837D1 (en) * 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3237814A1 (de) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. Wasserfreie emulsionen und verwendung derselben
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
CA1257199A (en) * 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
IL87219A0 (en) * 1987-08-07 1988-12-30 Abbott Lab Erythromycin formulations for oral administration

Also Published As

Publication number Publication date
DE59008336D1 (de) 1995-03-09
DE3919982A1 (de) 1990-12-20
JPH0334922A (ja) 1991-02-14
EP0403748B1 (de) 1995-01-25
EP0403748A2 (de) 1990-12-27
US5120710A (en) 1992-06-09
EP0403748A3 (de) 1992-07-08
ATE117547T1 (de) 1995-02-15

Similar Documents

Publication Publication Date Title
ES2066896T3 (es) Forma oral de farmaco de lipidos.
BR0108354A (pt) Carboidratos antiadesivos
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
ATE72990T1 (de) Pharmazeutische zusammensetzung vom fluessig/gel- phasenuebergangstyp.
PL261349A1 (en) Method of obtaining an incorporative complex of 7-isopropoxyisoflavone with cyclodextrin
ES2095964T3 (es) Una composicion de excipiente liquida que forma un gel.
AU668447B2 (en) Reversible, thermally gelling water-base medicinal composition
ECSP941148A (es) Medicamento en forma de comprimido con liberacion retardada de substancia activa
ES2128369T3 (es) Procedimiento para la fabricacion de formas farmaceuticas solidas con liberacion prolongada en dos etapas.
DE3583799D1 (de) Feste zubereitung mit langsamer freisetzung.
ES2037385T3 (es) Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
BR0111257A (pt) Formulação, e, uso de uma formulação
AR007649A1 (es) Composicion de relleno para forma de dosis farmaceutica de gelatina blanda y forma de dosis farmaceutica que la comprende
ATE156350T1 (de) Peptidarzneistoffe enthaltende pellets und ihre herstellung sowie deren verwendung
ES2045363T3 (es) Utilizacion de una composicion dietetica para la inhibicion de la adhesion celular.
KR890003379A (ko) 항-아테롬성 동맥경화제로서의 독사조신
ES2019595B3 (es) Empleo de glicofurol para licuacion de preparaciones medicas, para el llenado en capsulas de gelatina blanda
JPS6434909A (en) Cosmetic
IL97607A0 (en) Retinoids,their manufacture and pharmaceutical compositions containing them
ATE65395T1 (de) Acetylcystein enthaltendes, festes, wasserloeslisches arzneimittel.
ATE77555T1 (de) Guar-mehl.
BR0101120A (pt) Formulações orais de medicamentos
Selye Prevention of cardiac necrosis by amiloride
AR023668A1 (es) Nuevos derivados de benzoilguanidina con ventajosas propiedades, procedimiento para su preparacion y su utilizacion en la preparacion de medicamentos
KR880012518A (ko) 나프탈-아세트산 유도체를 함유하는 진통 및 소염제약 조성물

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 403748

Country of ref document: ES